Gene Variant Detail

Transcript	gDNA	cDNA	Protein	Source Database	Genome Build
NM_001378474.1	chr7:g.140753335_140753337	c.1798_1800	p.V600	RefSeq	GRCh38/hg38
NM_004333	chr7:g.140753335_140753337	c.1798_1800	p.V600	RefSeq	GRCh38/hg38
NM_001378468.1	chr7:g.140753335_140753337	c.1798_1800	p.V600	RefSeq	GRCh38/hg38
NM_001354609.2	chr7:g.140753335_140753337	c.1798_1800	p.V600	RefSeq	GRCh38/hg38
NM_004333.6	chr7:g.140753335_140753337	c.1798_1800	p.V600	RefSeq	GRCh38/hg38
XM_005250045	chr7:g.140753335_140753337	c.1798_1800	p.V600	RefSeq	GRCh38/hg38
NM_001354609.1	chr7:g.140753335_140753337	c.1798_1800	p.V600	RefSeq	GRCh38/hg38
NM_004333.5	chr7:g.140753335_140753337	c.1798_1800	p.V600	RefSeq	GRCh38/hg38

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT04302025	Phase II	Cobimetinib + Vemurafenib Entrectinib Atezolizumab Alectinib Pralsetinib	A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT01946789	Phase I	Nogapendekin alfa inbakicept	A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors	Completed	USA	0
NCT02296112	Phase II	Trametinib	Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations	Completed	USA	0
NCT04511013	Phase II	Ipilimumab + Nivolumab Binimetinib + Encorafenib + Nivolumab	A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases	Recruiting	USA	0
NCT02091141	Phase II	Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab	My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors	Completed	USA	0
NCT05159245	Phase II	Vemurafenib Tepotinib Vismodegib Apalutamide Alectinib Regorafenib Entrectinib Pertuzumab + Trastuzumab Pemigatinib Atezolizumab Cobimetinib Dabrafenib + Trametinib Dabrafenib Trametinib Abemaciclib	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE)	Recruiting	FIN	0
NCT05768178	Phase II	Cobimetinib + Vemurafenib	DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. (DETERMINE)	Recruiting	GBR	0
NCT04375527	Phase II	Binimetinib + Nivolumab	Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma	Recruiting	USA	0
NCT03332589	Phase I	Dabrafenib + E6201 E6201	E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)	Terminated	USA	0
NCT01954043	Phase I	Dabrafenib + Rabeprazole + Rifampin	A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors	Completed	USA \| GBR \| AUS	0
NCT03543969	Phase I	Cobimetinib + Vemurafenib	Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma	Active, not recruiting	USA	0
NCT03446157	Phase II	Cetuximab + Palbociclib	Palbociclib and Cetuximab in Metastatic Colorectal Cancer	Active, not recruiting	USA	0
NCT04221438	Phase II	Binimetinib + Encorafenib	Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement	Active, not recruiting	USA	0
NCT01844674	Phase I	Tizanidine + Vemurafenib	A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies	Completed	USA \| CYP \| CAN \| BRA	1
NCT02428712	Phase Ib/II	PLX8394	A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors	Completed	USA	0
NCT01820364	Phase II	Binimetinib + Encorafenib Encorafenib + Ribociclib Buparlisib + Encorafenib Encorafenib + Infigratinib Capmatinib + Encorafenib	LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma	Terminated	USA \| ESP \| DEU \| CHE \| CAN \| AUS	0
NCT02974803	Phase II	Dabrafenib + Trametinib	Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases	Terminated	CAN	0
NCT01683188	Phase III	Aldesleukin + Vemurafenib	HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma	Terminated	USA	0
NCT05099003	Phase Ib/II	Selinexor	A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)	Recruiting	USA \| NZL \| CAN \| AUS	0
NCT05538130	Phase I	PF-07799544 Encorafenib + PF-07799544 PF-07284890 + PF-07799544 PF-07799544 + PF-07799933	A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors	Recruiting	USA \| CAN	0
NCT03220035	Phase II	Vemurafenib	Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	Active, not recruiting	USA	1
NCT06270082	Phase I	IK-595	Study of IK-595 in RAS- or RAF-altered Advanced Tumors	Recruiting	USA	0
NCT01524978	Phase II	Vemurafenib Cetuximab	A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers	Completed	USA \| GBR \| FRA \| ESP \| DEU	1
NCT02263898	Phase II	Binimetinib + Encorafenib	Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations	Withdrawn	USA	0
NCT01907802	Phase I	Dabrafenib	Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction	Terminated	USA \| CAN	0
NCT04059224	Phase II	Dabrafenib + Trametinib	TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma (TraMel-WT)	Completed	BEL	0
NCT03273153	Phase III	Pembrolizumab Atezolizumab + Cobimetinib	A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma	Terminated	USA \| POL \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| BRA \| BEL \| AUS	2
NCT05050006	Phase II	ITIL-168	ITIL-168 in Advanced Melanoma (DELTA-1)	Terminated	USA \| GBR \| CAN	0
NCT02145910	Phase I	Vemurafenib	Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases	Withdrawn		0
NCT04587128	Phase II	Cetuximab Cetuximab + Irinotecan Panitumumab Irinotecan + Panitumumab	Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC	Recruiting	USA	0
NCT01826448	Phase I	Pexidartinib + Vemurafenib	A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma	Terminated	USA \| FRA \| DEU	0
NCT04324112	Phase II	Binimetinib + Encorafenib	Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL	Recruiting	USA	0
NCT04341181	Phase II	Atezolizumab Niraparib Erlotinib Axitinib Cobimetinib + Vemurafenib Avelumab Pertuzumab + Trastuzumab Vismodegib Alectinib Ado-trastuzumab emtansine	ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (ProTarget)	Recruiting	DNK	0
NCT05356897	Phase II	Trastuzumab + Trifluridine-tipiracil hydrochloride + Tucatinib	Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study	Withdrawn	USA	0
NCT02906059	Phase I	Adavosertib + Irinotecan	Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer	Completed	USA	0
NCT06024174	Phase Ib/II	Adagrasib + BBP-398 + Cetuximab Adagrasib + BBP-398	A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors	Terminated	USA \| ISR \| FRA \| FIN \| AUS	0
NCT04488003	Phase II	Ulixertinib	Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations	Terminated	USA	0
NCT03864042	Phase I	Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole Modafinil Bupropion + Rosuvastatin Binimetinib + Encorafenib	Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors	Completed	USA \| NLD \| ESP \| CAN \| BEL	0
NCT02908672	Phase III	Cobimetinib + Vemurafenib Atezolizumab + Cobimetinib + Vemurafenib	A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma	Completed	USA \| POL \| NZL \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT \| AUS	3
NCT02094872	Phase II	Doxorubicin	Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic	Completed	USA	0
NCT03911869	Phase II	Binimetinib + Encorafenib	An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS)	Terminated	USA \| ITA \| BEL \| AUS \| ARG	0
NCT04145297	Phase I	Hydroxychloroquine + Ulixertinib	Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas (UTAH)	Completed	USA	0
NCT01894672	Phase II	Encorafenib	BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation	Completed	USA	0
NCT03377361	Phase Ib/II	Regorafenib Ipilimumab + Nivolumab + Trametinib Nivolumab + Trametinib	An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread (CheckMate 9N9)	Active, not recruiting	USA \| ITA \| ESP \| DEU \| CZE \| CAN \| BEL \| AUS \| ARG	1
NCT05358548	Phase II	Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Fluorouracil + Pembrolizumab	ATATcH Alternating Treatment Plans for Advanced Cancer	Recruiting	USA	0
NCT03754179	Phase Ib/II	Dabrafenib + Hydroxychloroquine + Trametinib	Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma (COMBI-R2)	Unknown status	BEL	0
NCT03005639	Phase II	Cobimetinib + Vemurafenib	ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma	Withdrawn	USA	0
NCT02314481	Phase II	Vemurafenib Atezolizumab Alectinib Ado-trastuzumab emtansine	Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII)	Active, not recruiting	GBR	0
NCT02124772	Phase I	Trametinib Dabrafenib + Trametinib	Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations	Completed	USA \| GBR \| FRA \| CAN \| AUS	0
NCT01738451	Phase I	Dabrafenib	A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors	Completed	USA \| GBR \| AUS	0
NCT04462471	Phase I	Copanlisib + Vemurafenib	Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers	Completed	USA	0
NCT02278133	Phase Ib/II	Cetuximab + Encorafenib + LGK974	Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations	Completed	USA \| NLD \| ITA \| ISR \| FRA \| ESP \| CAN \| BEL \| AUS	1
NCT04741997	Phase I	Binimetinib + Encorafenib + Nivolumab Binimetinib + Encorafenib	Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma	Recruiting	USA	0
NCT01739764	Phase III	Vemurafenib	An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol	Completed	USA \| ROU \| NZL \| NLD \| ITA \| ISR \| HUN \| HRV \| GRC \| GBR \| FRA \| ESP \| DEU \| CYP \| CAN \| BRA \| BEL	8
NCT02230306	Phase II	Cobimetinib + Vemurafenib	Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases	Terminated	USA	0
NCT02039947	Phase II	Dabrafenib + Trametinib	Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain	Completed	USA \| ITA \| FRA \| ESP \| DEU \| CAN \| AUS	0
NCT04249843	Phase I	BGB3245	Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors	Recruiting	USA \| AUS	0
NCT05388877	Phase I	Dabrafenib + E6201	E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma	Recruiting	USA	0
NCT03297606	Phase II	Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR)	Recruiting	CAN	0
NCT01562899	Phase II	Binimetinib + Ganitumab	A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors	Terminated	USA \| ITA \| GBR \| FRA \| ESP \| CAN \| BEL \| AUS	0
NCT03149029	Phase II	Dabrafenib + Pembrolizumab + Trametinib Pembrolizumab + Trametinib	Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma	Active, not recruiting	USA	0
NCT02145143	Phase 0	Vemurafenib	Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study	Active, not recruiting	USA	0
NCT03919071	Phase II	Dabrafenib + Trametinib	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	Recruiting	USA	1
NCT02036086	Phase II	Cobimetinib + Vemurafenib	Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases	Unknown status	CAN	0
NCT01603212	Phase Ib/II	Aldesleukin + Alpha 2 Interferon + Vemurafenib	Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor	Completed	USA	0
NCT03087071	Phase II	Panitumumab Panitumumab + Trametinib	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	Active, not recruiting	USA	0
NCT04952753	Phase II	Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NIS793 Bevacizumab + Fluorouracil + Leucovorin + NIS793 + Oxaliplatin	Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3)	Active, not recruiting	USA \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BEL \| AUS	5
NCT01701037	Phase II	Dabrafenib + Trametinib Dabrafenib	Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery	Terminated	USA	0
NCT04544111	Phase II	Dabrafenib + Spartalizumab Spartalizumab + Trametinib	PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer	Active, not recruiting	USA	0
NCT02721459	Phase I	Cobimetinib + Vemurafenib + XL888	XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma	Active, not recruiting	USA	0
NCT01436656	Phase I	Encorafenib	A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma	Completed	USA \| NOR \| FRA \| ESP \| CHE \| AUS	1
NCT05275374	Phase Ib/II	BI 882370 + Trametinib BI 882370	XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)	Not yet recruiting		0
NCT01787500	Phase I	Cetuximab + Irinotecan + Vemurafenib	Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery	Active, not recruiting	USA	0
NCT02967692	Phase III	Dabrafenib + Spartalizumab + Trametinib Dabrafenib + Trametinib	A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i)	Completed	USA \| SWE \| POL \| NOR \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG	6
NCT04417621	Phase II	LTT462 + LXH 254 Trametinib Ribociclib	Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma	Active, not recruiting	USA \| NOR \| NLD \| ITA \| ISR \| GBR \| FRA \| DEU \| CHE \| BEL \| AUS \| ARG	0
NCT01942993	Phase II	Vemurafenib	The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma	Terminated	USA	0
NCT01813214	Phase II	Vemurafenib	The Effects of Vemurafenib on Immunity in Patients With Melanoma	Terminated	USA	0
NCT04903119	Phase I	Dabrafenib + Nilotinib + Trametinib	Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma	Recruiting	USA	0
NCT01777776	Phase Ib/II	Encorafenib Encorafenib + Ribociclib	Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.	Terminated	USA \| NLD \| CAN \| AUS	0
NCT01981187	Phase II	Encorafenib	LGX818 for Patients With BRAFV600 Mutated Tumors	Terminated	USA	0
NCT03992456	Phase II	Panitumumab Regorafenib Trifluridine-tipiracil hydrochloride	Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer	Active, not recruiting	USA	0
NCT01974258	Phase I	Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib	Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients	Withdrawn	USA	0
NCT02068079	Phase I	Trientine + Vemurafenib	A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma	Withdrawn	USA	0
NCT05203172	FDA approved	Encorafenib Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib Binimetinib + Cetuximab + Encorafenib Binimetinib	The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials	Recruiting	USA \| SVK \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| AUS	4
NCT05668585	Phase Ib/II	Cetuximab + CFT1946 CFT1946 + Trametinib CFT1946	A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors	Recruiting	USA \| FRA \| ESP	0
NCT03178851	Phase I	Atezolizumab Atezolizumab + Cobimetinib	Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma	Completed	USA \| ESP \| BRA \| AUS	3
NCT03581292	Phase II	Temozolomide + Veliparib Veliparib	Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations	Active, not recruiting	USA \| NZL \| CAN \| AUS	1
NCT05299580	Phase II	Dabrafenib + Trametinib	Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)	Withdrawn	ITA	0
NCT02456701	Phase I	CDX-3379 + Vemurafenib	Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379	Completed	USA	0
NCT04543188	Phase I	Binimetinib + Midazolam + PF-07284890 Binimetinib + PF-07284890 PF-07284890	A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement	Terminated	USA \| ISR \| CAN	0
NCT03793179	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pemetrexed Disodium	Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer	Active, not recruiting	USA \| CAN	1
NCT02159066	Phase II	Binimetinib + Encorafenib + Ribociclib Binimetinib + Encorafenib Binimetinib + Capmatinib + Encorafenib Binimetinib + Buparlisib + Encorafenib Binimetinib + Encorafenib + Infigratinib	LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma	Completed	USA \| NLD \| ITA \| GBR \| ESP \| DEU \| CHE \| CAN \| AUS	0
NCT02082665	Phase I	Dabrafenib + Midazolam + Rosuvastatin	Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam	Completed	USA \| ESP	0
NCT01902173	Phase Ib/II	Dabrafenib + Trametinib + Uprosertib Dabrafenib + Uprosertib	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	Active, not recruiting	USA	0
NCT05221320	Phase II	Hydroxychloroquine + Ulixertinib	Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies	Terminated	USA	0
NCT04418167	Phase I	JSI-1187 Dabrafenib + JSI-1187	JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations	Suspended	USA	0
NCT01843738	Phase I	Vemurafenib	Radiation Use During Vemurafenib Treatment	Withdrawn	USA	0
NCT06011772	Phase I	CIMAvax-EGF Bevacizumab + Cetuximab + CIMAvax-EGF + Leucovorin Bevacizumab + CIMAvax-EGF + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + CIMAvax-EGF + Fluorouracil + Oxaliplatin Cetuximab + CIMAvax-EGF + Fluorouracil + Irinotecan + Leucovorin	EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer	Recruiting	USA	0
NCT04720768	Phase Ib/II	Binimetinib + Encorafenib + Palbociclib	Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE (CELEBRATE)	Recruiting	AUS	0
NCT04294160	Phase I	Dabrafenib + LTT462 + Spartalizumab Dabrafenib + LTT462 + TNO155 Dabrafenib + TNO155 + Trametinib Dabrafenib + LTT462 Dabrafenib + LTT462 + LXH 254 Dabrafenib + LTT462 + Trametinib	A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer	Terminated	USA \| NLD \| ISR \| GBR \| ESP \| DEU \| CAN \| BEL \| AUS	1
NCT05355701	Phase I	Binimetinib + PF-07799933 PF-07799933 Cetuximab + PF-07799933	A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.	Recruiting	USA \| ISR \| CAN	0
NCT04923126	Phase Ib/II	PD-0325901	SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma	Recruiting	USA	0
NCT03592641	Phase II	Savolitinib	Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer	Terminated	USA	0
NCT04190628	Phase I	ABM-1310 ABM-1310 + Cobimetinib	Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors	Terminated	USA	0
NCT01656642	Phase I	Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Vemurafenib	A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma	Completed	USA	0
NCT01677741	Phase I	Dabrafenib	A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects	Completed	USA \| ITA \| ISR \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| AUS	0
NCT03301636	Phase II	Indoximod + Nivolumab Indoximod + Pembrolizumab	A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma (NLG2107)	Terminated	USA	0
NCT01767623	Phase I	Vemurafenib	A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients	Completed	USA \| TUR \| ISR \| GRC \| GBR \| AUS	1
NCT05722886	Phase II	Cobimetinib + Vemurafenib Alectinib Pertuzumab + Trastuzumab Entrectinib Atezolizumab	DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)	Recruiting	GBR	0
NCT03442569	Phase II	Ipilimumab + Nivolumab + Panitumumab	PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC	Active, not recruiting	USA	0
NCT05180825	Phase II	Vinblastine Trametinib	Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy (PLGG - MEKTRIC)	Recruiting	FRA	0
NCT05593328	Phase II	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib Bevacizumab + Fluorouracil + Irinotecan + Leucovorin	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation	Active, not recruiting	USA	0
NCT05215340	Phase III	Pembrolizumab Datopotamab deruxtecan + Pembrolizumab	Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)	Recruiting	USA \| TUR \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	9
NCT01543698	Phase Ib/II	Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib	A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors	Completed	USA \| ITA \| FRA \| ESP \| CHE \| CAN \| BEL \| AUS	1
NCT02723006	Phase I	Nivolumab + Tovorafenib MLN1202 + Nivolumab Ipilimumab + Nivolumab + Vedolizumab	Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma	Terminated	USA	0
NCT01519323	Phase I	Vemurafenib	BRIM-P	Terminated	USA \| SVK \| POL \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| AUS	0
NCT01835184	Phase I	Cabozantinib + Vemurafenib	Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery	Terminated	USA	0
NCT01619774	Phase II	Dabrafenib + Trametinib	An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor	Completed	USA	0
NCT03155620	Phase II	Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Recruiting	USA \| CAN \| AUS	1
NCT02961283	Phase I	ASN003	Study of ASN003 in Subjects With Advanced Solid Tumors	Terminated	USA	0
NCT06106308	Phase II	Fluorouracil + Irinotecan + Leucovorin + Onvansertib Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation	Recruiting	USA	0

Gene	BRAF
Variant	V600X
Impact List	missense
Protein Effect	unknown
Gene Variant Descriptions	BRAF V600X indicates any BRAF missense mutation that results in replacement of the valine (V) at amino acid 600 by a different amino acid. BRAF V600 mutations are hotspot mutations that often result in increased Braf kinase activity (PMID: 15035987).
Associated Drug Resistance
Category Variants Paths	BRAF mutant BRAF V600X

Gene Variant Detail

Contact

Filtering

Sorting

Filtering

Sorting